Research Paper Volume 15, Issue 9 pp 3295—3330

Proteostatic modulation in brain aging without associated Alzheimer’s disease-and age-related neuropathological changes

class="figure-viewer-img"

Figure 6. (A) Gel electrophoresis and western blotting to ermin (ERMN), β-tubulin III, vimentin (VIM), clathrin (heavy chain), SNAP25, VPS26, P20S α + β, and GSK3α/β in the FC area 8 across age; group 1 (young): 30–44y, group 2 (middle-aged: MA): 45–52y; group 3 (early-elderly): 64–70y; and group 4 (late-elderly): 75–85y. Significantly decreased expression levels of ERMN are found in group 4 compared with group 1 and group 2 (p < 0.05). Clathrin expression is significantly increased in group 4 compared with groups 1, 2, and 3 (p < 0.01). In contrast, there is a significant reduction of SNAP25 levels in groups 2, 3, and 4 compared with group 1 (p < 0.001), and VPS26 in groups 3 and 4 compared with group 1 (p < 0.05). P20S α + β levels are reduced in groups 3 and 4 compared with group 1 (p < 0.05). Similarly, reduced levels in GSK3α/β are observed in aging, reaching significant differences between group 1 and group 4 (p < 0.05). (B) Decreased levels of ERMN, VPS26 and P20S α + β significantly correlate with age. Pearson’s correlation significance level set at p < 0.05.